As compared with Q3 FY22, the companys net profit and revenue have declined by 37% and 14%, respectively. Total expenses increased by 31% to Rs 87.70 crore in Q4 FY22 over Q4 FY21. Profit before tax in Q4 FY22 stood at Rs 16.77 crore, up by 10% from Rs 15.31 crore in Q4 FY21. The companys consolidated net profit increased by 11% to Rs 69.35 crore on a 11% rise in revenue from operations to Rs 472.12 crore in Q4 FY22 over Q4 FY21. The company has recommended a dividend of Rs 1.50 per share for the FY 2021-22. Mahendra Patel, managing director, Lincoln Pharmaceuticals, said, Companys expansion plans for Cephalosporin products and foray in EU and Australian markets are also progressing well. Lincoln Pharmaceuticals hasdeveloped 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio lnantl-Infectlve, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company has its strong presence in domestic market with good strength of own field force and also exports to more than 60 countries. Powered by Capital Market - Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.